Stability of cefodizime in solution and compatibility with other injectable drugs. 1994

M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
Institute of Immunology and Infectious Diseases, University of Verona, Ospedale Civile Maggiore, Italy.

The stability of cefodizime in five intravenous infusion fluids (0.9% sodium chloride, 5% dextrose in water, 10% dextrose in water, 5% amino acid injection, 3% polygeline) was studied at room temperature and at 4 degrees C. The compatibility of cefodizime with commonly used injectable drugs (ranitidine, metoclopramide, folinic acid, furosemide, aminophilline, methylprednisolone, betamethasone, hydrocortisone, dexamethasone, ketoprofen, noramidopyrine, acetylcysteine, digoxin, diazepam, acetylsalicylic acid, chlorpromazine, clonidine, clomipramine) was studied in 0.9% sodium chloride and 5% dextrose at room temperature. At intervals during the storage periods (up to 24 hrs at room temperature; up to 6 days at 4 degrees C) color, clarity and solution pH were examined; cefodizime content was determined by a microbiological method. Cefodizime concentrations remained greater than 90% of the initial concentrations in all infusion fluids for at least 24 hrs at room temperature and 6 days at 4 degrees C. No visual changes or appreciable changes in pH were observed for any of the solutions. Immediate clouding was observed when chlorpromazine was combined with the solution of cefodizime. A color change was observed when acetylcysteine was mixed with cefodizime. An increase in pH was noted when aminophilline was added to the solution of cefodizime. However, cefodizime concentrations remained greater than 90% of the initial concentrations of the solutions after mixture with all the tested drugs for at least 24 hrs at room temperature.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D004344 Drug Incompatibility The quality of not being miscible with another given substance without a chemical change. One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction. (Dorland, 27th ed; Stedman, 25th ed) Drug Incompatibilities,Incompatibilities, Drug,Incompatibility, Drug
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D012996 Solutions The homogeneous mixtures formed by the mixing of a solid, liquid, or gaseous substance (solute) with a liquid (the solvent), from which the dissolved substances can be recovered by physical processes. (From Grant & Hackh's Chemical Dictionary, 5th ed) Solution
D013696 Temperature The property of objects that determines the direction of heat flow when they are placed in direct thermal contact. The temperature is the energy of microscopic motions (vibrational and translational) of the particles of atoms. Temperatures

Related Publications

M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
January 1990, American journal of hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
October 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
May 1984, American journal of hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
July 1984, American journal of hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
July 1983, American journal of hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
July 2017, The Kobe journal of medical sciences,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
April 1986, American journal of hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
March 1990, American journal of hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
October 2020, Hospital pharmacy,
M Merighi, and A Carlotto, and L Guella, and S Bonora, and G C Fibbia, and R Mazzi, and L Lazzarini, and F Mirandola, and M Cruciani, and E Concia
September 1990, American journal of hospital pharmacy,
Copied contents to your clipboard!